The overexpression of EGFR in approximately 90% of HNSCC tumors [11,12,13] and the significant association of its overexpression with poor prognosis identified EGFR as a promising target for the treatment of HNSCC. The gene discussed is EGFR; the disease is head and neck squamous cell carcinoma.